Skip to contentI
iBio, Inc.
I
IBIOiBio, Inc. Q2 2018 · 10-Q
Revenue$153.00K$153.00K+104.0% vs Q2 2017 Net Income-$3.90M-$3.90MN/M vs Q2 2017 EPS Diluted-$0.41-$0.41N/M vs Q2 2017 Operating Income-$3,427,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
iBio, Inc. · CIK 1420720 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$3,769,000N/M Margins · derivedOperating margin-2239.9%+2193.5 pt vs Q2 2017
Net margin-2548.4%+1757.0 pt vs Q2 2017
ended Dec 31, 2017 · filed Feb 14, 2018 · 45 d after period end